Class / Patent application number | Description | Number of patent applications / Date published |
514353000 | Plural acyclic nitrogens bonded directly to the same carbon or bonded directly to each other | 13 |
20080319028 | Dicycloalkylcarbamoyl Ureas As Glucokinase Activators - This invention relates to dicycloalkylcarbamoyl ureas of formula (I), which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. | 12-25-2008 |
20090137641 | Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia-Like Symptoms - The present invention is directed to the prevention, reversal and medical treatment of dystonia and dyskinesia as well as other diseases related to movement disorders, both in human beings and animals by administering a neuronal potassium channel opener such as flupirtine, retigabine or maxipost. | 05-28-2009 |
20090149510 | Compositions and methods for modulating a kinase cascade - The invention relates to compounds and methods for modulating one or more components of a kinase cascade. | 06-11-2009 |
20090298891 | Methods of Treating or Preventing Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents - The present invention features methods of inhibiting ribonucleotide reductase and DNA synthesis after administration of a dose of ionizing radiation to cells. The present invention further features methods of treating patients suffering from cancer comprising contemporaneous or sequential administration of a radiosensitizing dose of a 2-carboxyaldehyde pyridine thiosemicarbazone compound and ionizing radiation. | 12-03-2009 |
20090318507 | Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms - The present invention is directed to the prevention, reversal and medical treatment of dystonia and dyskinesia as well as other diseases related to movement disorders, both in human beings and animals by administering a neuronal potassium channel opener such as flupirtine, retigabine or maxipost. | 12-24-2009 |
20110086891 | Solid Forms of 2-(2,4-Difluorophenyl)-6-(1-(2,6-Difluorophenyl)Ureido)Nicotinamide) - This invention relates to solid forms of 2-(2,4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide and pharmaceutical compositions thereof, and methods and uses therewith. | 04-14-2011 |
20120142743 | PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORMS OF FLUPIRTINE MALEATE - New polymorphic forms of flupirtine maleate are described. | 06-07-2012 |
20120238604 | CYTOTOXIC COMPOUNDS - The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt or solvate or thereof. In particular, the present invention relates to a method treating diseases involving cell proliferation, migration, apoptosis, or adhesion, comprising administering to a human or non-human mammalian patient an effective amount of a compound of general formula (I) or a pharmaceutically acceptable salt or solvate or thereof. | 09-20-2012 |
20120309797 | PYRIDYL CYANOGUANIDINE DERIVATIVES - Compounds of formula (I) or pharmaceutically acceptable salts thereof, and use for treating cancer thereof are disclosed, wherein, the definitions of X, Y, R | 12-06-2012 |
20130096163 | Injectable dosage form of flupirtine - The present invention relates to a flupirtine-containing lyophilisate, the use of this lyophilisate to produce a pharmaceutical composition to be parenterally applied, a procedure to produce a flupirtine-containing pharmaceutical composition to be parenterally applied, and a procedure to produce the flupirtine-containing lyophilisate as well as the flupirtine-containing pharmaceutical composition produced using the lyophilisate. For this purpose a lyophilisate is provided which contains the active ingredient flupirtine in the form of a physiologically tolerated salt, which has a solubility in water of at least 2.5 mg/ml, preferably at least 5 mg/ml, especially preferably at least 10 mg/ml, and contains one or more cyclodextrins or cyclodextrin derivatives, and which may be used to produce a pharmaceutical composition to be parenterally applied. | 04-18-2013 |
20130261157 | Novel multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid - The invention relates to novel multicomponent crystals, to the production thereof, and to the use thereof for treating pain conditions, in particular of unclear genesis, by means of a simultaneous effect on pains which are caused by muscle tension or degenerative joint diseases as well as on pains that are based on inflammatory processes. The novel multicomponent crystals contain ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester (flupirtine) and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid (diclofenac) as the sole active ingredient combination and can be produced by dissolving the two components in a molar ratio of 1.0:0.9 to 1.0:1.1 in an inert organic solvent and subsequently crystallizing the complex compound. | 10-03-2013 |
20130267567 | Novel multicomponent crystals made of ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and an arylpropionic acid - The invention relates to novel multicomponent crystals, to the production thereof, and to the use thereof for treating pain conditions, in particular of unclear genesis, by means of a simultaneous effect on pains which are caused by muscle tension or degenerative joint diseases as well as on pains that are caused by inflammatory processes. The multicomponent crystals according to the invention contain ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester (flupirtine) and an arylpropionic acid as the sole active ingredient combination and can be produced by dissolving flupirtine and the arylpropionic acid in an inert organic solvent and subsequently crystallizing the multicomponent crystal. | 10-10-2013 |
20130281494 | POLYMORPHS OF N-(6-(4-CHLOROPHENOXY)HEXYL)-N'-CYANO-N"-(4-PYRIDYL)GUANIDINE, AND PREPARATION THEREOF AND USE THEREOF - Disclosed are a polymorphs I-VI of N-(6-(4-chlorophenoxy)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine or of a solvate thereof, a preparation method thereof, and a use thereof as a biological active ingredient. The polymorphs are useful in treatment of cancers, and diseases or disorders caused by abnormal cell proliferation. | 10-24-2013 |